Influence of p53 mutations on prognosis of patients with glioblastoma

Cancer

Volumn 95, Issue 2, 2002, Pages 249-257

  Shiraishi, Shoji ^a   Tada, Kenji ^a   Nakamura, Hideo ^a   Makino, Keishi ^a   Kochi, Masato ^a   Saya, Hideyuki ^a   Kuratsu, Jun Ichi ^b   Ushio, Yukitaka ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Astrocytoma; Glioblastoma; p53; Prognosis; Tumorigenesis; Yeast functional assay

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CHILD; DNA SEQUENCE; FEMALE; GENE LOCUS; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ASTROCYTOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, P53; GLIOBLASTOMA; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SEQUENCE ANALYSIS, DNA; SURVIVAL RATE;

EID: 0037099758     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10677     Document Type: Article

References (50)

1. Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay
2. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas
3. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
4. Genetic alterations associated with the evolution and progression of astrocytic brain tumors
5. Overexpression of the EGF receptor and p55 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
6. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
7. Deletion of p16 and p15 in brain tumors
8. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
9. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations
10. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas
11. Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas
12. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
13. Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor
14. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme
15. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression
16. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies
17. Comparative study of p53 gene and protein alterations in human astrocytic tumors
18. A case history of glioma progression
19. p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma
20. p53 status has no prognostic significance in glioblastomas treated with radiotherapy
21. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes
22. Selective sensitivity to radiation of cerebral glioblastoma harboring p53 mutation
23. Genetic sub-types of human malignant astrocytoma correlate with survival
24. The challenge of p53 as prognostic and predictive factor in gliomas
25. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors
26. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients
27. Clonality and stability of the p53 gene in human astrocytic tumor cells: Quantitative analysis of p53 gene mutations by yeast functional assay
28. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme
29. p53 protein accumulation and gene mutations in human glioma cell lines
30. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: Comparison with conventional structural analyses
31. A simple p53 functional assay for screening cell lines, blood, and tumors
32. Adenovirusmediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
33. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
34. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
35. Increased levels of p21 WAF1/CIP1 in human brain tumors
36. Aberrant p21 regulation in radioresistant primary glioblastoma multiforme cells bearing wild-type p53
37. Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1, 3-bis(2-chloroethyl)-1-nitrosourea and cisplatin
38. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy
39. The Ink4a tumor suppressor gene product, p19 Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
40. Association of p19 ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
41. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms
42. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells
43. p76 MDM2 inhibits the ability of p90 MDM2 to destabilize p53
44. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53
45. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by ser-46-phosphorylated p53
46. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis
47. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
48. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay
49. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer